Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of [68Ga]Ga-A9-6217, [177Lu]Lu-A9-0631, and [225Ac]Ac-A9-0642 in adults with GRPR-positive solid tumors
PACTR202608802549963Phase 1Not yet recruiting
- Sponsor
- Alpha-9 Oncology
- Start
- Jul 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [68Ga]Ga-A9-6217, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 in cancer and Nonhematologic neoplasms, sponsored by Alpha-9 Oncology. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
[68Ga]Ga-A9-6217[177Lu]Lu-A9-0631[225Ac]Ac-A9-0642
03
Conditions
cancerNonhematologic neoplasms
Beyond the preview
Go deeper on PACTR202608802549963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202608802549963.